chcr logo

A Population-Based Approach to Survivorship Care: Delivering Interventions via the Web


This is a prospective study in a population-based sample of patients treated in diverse clinical settings. Participant surveys, SEER registry data, and data on use of the web portal is combined into a single dataset to address the aims and hypotheses proposed above. Our primary goal is to assess the feasibility of recruiting patients to a web-based intervention. Patient participants are invited to complete a survey and then to use the web portal for 4 months. A brief evaluation of the portal by the patient participants will follow. Portal non-users or low users (one visit only) will also be surveyed and invited to provide information on why they did not visit or use the portal.


Aim 1. To identify patient demographic and clinical factors associated with use of the web-based portal. Using the population-based sampling approach we describe below, we sample a more diverse population than was included in the pilot study of the web portal. We expect that age will be associated with lower likelihood of accessing the web portal and that patients with higher stage disease will have higher rates of use.

Aim 2.
To evaluate the relationship between unmet information needs and treatment complexity (number of treatment modalities) and use of the web portal in the sample of participants who complete a baseline survey. We expect that unmet information needs and greater treatment complexity will be associated with higher rates of use of the web portal. Use rates are measured as any use vs. low use (one log in session)/no use.

Aim 3.
To investigate factors associated with frequency of use among those patients who access the web portal.


We invite 300 patients to participate. Eligibility criteria are broad and include being 21 years of age or older, a diagnosis of a first non-invasive, non-metastatic invasive breast cancer (Stages 0, I, II, III), and the ability to read English and give informed consent. Patients with a previous cancer except non-melanomatous skin cancers or non-breast in situ cancers and men with breast cancer are ineligible.

Related Projects